Equities

Amicus Therapeutics Inc

Amicus Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.99
  • Today's Change0.01 / 0.09%
  • Shares traded2.10m
  • 1 Year change-3.26%
  • Beta0.6245
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy5
Outperform6
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Amicus Therapeutics, Inc. have a median target of 18.00, with a high estimate of 21.00 and a low estimate of 14.00. The median estimate represents a 63.79% increase from the last price of 10.99.
High91.1%21.00
Med63.8%18.00
Low27.4%14.00

Earnings history & estimates in USD

On Nov 06, 2024, Amicus Therapeutics, Inc. reported 3rd quarter 2024 losses of -0.02 per share. This result was in line with the consensus of the 9 analysts following the company and exceeded last year's 3rd quarter results by 71.43%.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+6.54%
Amicus Therapeutics, Inc. reported annual 2023 losses of -0.51 per share on Feb 28, 2024.
Average growth rate+22.60%
More ▼

Revenue history & estimates in USD

Amicus Therapeutics, Inc. had 3rd quarter 2024 revenues of 141.52m. This bettered the 135.33m consensus of the 12 analysts covering the company. This was 64.04% above the prior year's 3rd quarter results.
Average growth rate+8.39%
Amicus Therapeutics, Inc. had revenues for the full year 2023 of 399.36m. This was 21.30% above the prior year's results.
Average growth rate+22.33%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.